All In Biotech

Drug Trial Radar · NCT05329766

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 332 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

332

Actual

Start

Jun 10, 2022

Primary completion

Sep 7, 2026

Study completion Sep 7, 2026

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
Gilead Sciences
First posted
Apr 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).

Conditions

  • Gastrointestinal Tract Malignancies

Interventions

  • DomvanalimabDrug

    Administered as specified in the treatment arm

  • QuemliclustatDrug

    Administered as specified in the treatment arm

  • ZimberelimabDrug

    Administered as specified in the treatment arm

  • FluorouracilDrug

    Administered as specified in the treatment arm

  • LeucovorinDrug

    Administered as specified in the treatment arm

  • OxaliplatinDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Up to 18 months
  2. Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to 18 months

Locations

43 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Los Angeles, California

  • Research Site

    Santa Monica, California

  • Research Site

    Derby, Connecticut

  • Research Site

    Fort Myers, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Boston, Massachusetts

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Columbus, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Portland, Oregon

  • Research Site

    Nashville, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Fairfax, Virginia

  • Research Site

    Toronto, Canada

  • Research Site

    Las Condes, Chile

  • Research Site

    Recoleta, Chile

  • Research Site

    Santiago, Chile

  • Research Site

    Talca, Chile

  • Research Site

    Bordeaux, France

  • Research Site

    Brest, France

  • Research Site

    Caen, France

  • Research Site

    Lille, France

  • Research Site

    Lyon, France

  • Research Site

    Marseille, France

  • Research Site

    Montpellier, France

  • Research Site

    Plérin, France

  • Research Site

    Poitiers, France

  • Research Site

    Rouen, France

  • Research Site

    Toulouse, France

  • Research Site

    Villejuif, France

  • Research Site

    Belgrade, Serbia

  • Research Site

    Kamenitz, Serbia

  • Research Site

    Kragujevac, Serbia

  • Research Site

    Busan, South Korea

  • Research Site

    Daegu, South Korea

  • Research Site

    Hwasun, South Korea

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.